Dey L.P. And Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets For The Chronic Treatment Of Asthma

Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced that it has launched ZYFLO CR(TM) (zileuton) extended release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older. [click link for full article]

More: continued here

Filed under: Clinical Trials on September 28th, 2007